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In the Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL)
trial (atorvastatin 80 mg vs simvastatin 20 to 40 mg), the Treating to New Targets (TNT)
trial (atorvastatin 80 vs 10 mg), the Stroke Prevention by Aggressive Reduction in
Cholesterol Levels (SPARCL) trial (atorvastatin 80 mg vs placebo), and the Collaborative
Atorvastatin Diabetes Study (CARDS), the Anglo-Scandinavian Cardiac Outcomes Trial
(ASCOT), and the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints
in Non-Insulin-Dependent Diabetes Mellitus (ASPEN) (atorvastatin 10 mg vs placebo),
lipid changes on treatment were compared between genders with studies grouped by dose.
The association of on-study low-density lipoprotein (LDL) cholesterol and CV events by
gender was evaluated in the combined studies and the impact of gender on adverse events in
each study separately. Major CV events occurred in 3,083 of 30,000 men (10.3%) and 823 of
9,173 women (9.0%). Changes in lipids were similar in women and men. Major CV events
were associated with gender-speciﬁc quintiles of on-treatment LDL cholesterol for women
and men. In women, LDL cholesterol was a signiﬁcant predictor of stroke, but not in men.
Discontinuation rates due to adverse events were higher in women in 4 of 6 trials, but in
only 1 trial was a signiﬁcant treatment-gender interaction seen. Myalgia rates were slightly
higher in women in both statin and placebo groups. In conclusion, the response of women to
atorvastatin was similar to that of men, with slightly more discontinuations due to adverse
events. Higher on-treatment LDL cholesterol was signiﬁcantly associated with more CV
events in both genders, but the association was stronger for stroke in women and for cor-
onary heart disease death in men.  2015 Elsevier Inc. All rights reserved. (Am J Cardiol
2015;115:447e453)Lipid-lowering therapy with statins decreases cardiovas-
cular (CV) events and mortality in a variety of patient pop-
ulations and clinical scenarios.1,2 Fewer women than men
have been enrolled in statin trials, and whether statins provide
beneﬁt to certain subsets of women has been controversial.
For example, a meta-analysis of 6 trials including 11,435
women without CV disease published a decade ago showed
no beneﬁt for statins for any of the CV end points, although
beneﬁt was seen for secondary prevention.3 In ameta-analysis
of statins for primary prevention in women published 6 years
later with larger numbers of subjects,4 the relative risk for CV
events for statin-treated women was 0.63 (95% conﬁdence
interval [CI] 0.49 to 0.82, p <0.001), with a trend toward a
reduction in total mortality (relative risk 0.78, 95% CI 0.53 toardiology, San Francisco General Hospital, San Fran-
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0.1016/j.amjcard.2014.11.0261.15). Two recent meta-analyses came to opposite conclu-
sions. Gutierrez et al5 concluded that statins for secondary
prevention reduced total mortality and stroke in men but not
women, while Kostis et al6 showed similar beneﬁts for men
and women in primary and secondary prevention, including
similar reductions in total mortality.
In most statin trials, adverse events have not been reported
according to gender and have not included data on each in-
dividual patient. Some evidence suggests that statin discon-
tinuation rates are higher in women,7 and despite objective
evidence, women are generally considered to be more likely
than men to have side effects related to statins. Given these
considerations, the purpose of this study was to evaluate the
impact of female gender on lipid lowering, CV events, and
adverse events (AE) in 6 large randomized clinical trials using
patient-level data. These trials included atorvastatin at high
and low doses in the settings of primary and secondary pre-
vention: Treating to New Targets (TNT),8 Incremental
Decrease in End Points Through Aggressive Lipid Lowering
(IDEAL),9 Stroke Prevention by Aggressive Reduction in
Cholesterol Levels (SPARCL),10 the Collaborative Atorvas-
tatin Diabetes Study (CARDS),11 Atorvastatin Study for
Prevention of Coronary Heart Disease Endpoints in Non-
Insulin-Dependent Diabetes Mellitus (ASPEN),12 and the
Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).13www.ajconline.org
Table 1
Features of the trials
Variable TNT IDEAL SPARCL CARDS ASPEN ASCOT-LLA
Study Drug A 80 mg A 80 mg A 80 mg A 10 mg A 10 mg A 10 mg
Comparator A 10 mg S 20-40 mg Placebo Placebo Placebo Placebo
Patients 10,001 8,888 4,731 2,838 2,410 10,305
Women 1,902 (19.0%) 1,701 (19.1%) 1,908 (40.3%) 909 (32.3%) 811 (33.7%) 1,942 (18.8%)
Mean FU 4.9 years 4.8 years 4.9 years 3.9 years* 4 years 3.3 years*
Entry criteria CHD, LDL 130-
250 mg/dl
History of MI Stroke or TIA 1-6
months
Diabetesþ another
RF, no CAD
Diabetes Hypertension þ 3
RFs, no CAD
Primary endpoint CHD death, MI,
stroke, cardiac
arrest
CHD death, MI,
cardiac arrest
Fatal or non-fatal
stroke
CHD death, MI,
UA, stroke
cardiac arrest,
PCI, CABG
CHD death, MI,
UA, stroke
cardiac arrest,
PCI, CABG
CHD death, MI
Baseline LDL-C
(mg/dl)
98 121 133 117 113 133
On-treatment
LDL-C (mg/dl)
77 vs 101 81 vs 104 73 vs 129 75 vs 119 79 vs 113 87 vs 131
Event rates 8.7 vs 10.9% 9.3 vs 10.4% 11.2 vs 13.1% 5.8 vs 9.0% 13.7 vs 15.0% 1.9 vs 3.0%
HR (95% CI) 0.78 (0.69-0.89) 0.89 (0.78-1.01) 0.84 (0.71-0.99) 0.63 (0.48-0.83) 0.90 (0.73-1.12) 0.64 (0.50-0.83)
A ¼ atorvastatin; CABG ¼ coronary artery bypass grafting; CHD ¼ coronary heart disease; MI ¼ myocardial infarction; PCI ¼ percutaneous coronary
intervention; RF ¼ risk factor; S ¼ simvastatin; TIA ¼ transient ischemic attack; UA ¼ unstable angina.
* Stopped early because of beneﬁt.
Table 2
Clinical features of women and men in the trials
Variable Women
(n¼9,173)
Men
(n¼30,000)
P value
Age (years) 63.39.4 61.69.1 <0.0001
Diabetes mellitus 3,269 (35.6%) 7,870 (26.2%) <0.0001
Hypertension 6,467 (70.5%) 18,686 (62.3%) <0.0001
Current smoker 1,939 (21.1%) 6,450 (21.5%) 0.75
Body mass index (Kg/m2) 28.65.2 28.14.1 <0.0001
Body weight (Kg) 74.614.5 86.114.0 <0.0001
Systolic BP (mmHg) 143.722.4 142.822.5 0.0015
Diastolic BP (mmHg) 82.111.6 84.412.2 <0.0001
Total cholesterol (mg/dl) 207.534.5 194.434.2 <0.0001
LDL-C (mg/dl) 122.031.1 117.730.1 <0.0001
HDL-C (mg/dl) 55.014.5 46.811.8 <0.0001
Triglycerides (mg/dl) 153.378.3 150.282.3 0.0017
ApoA1 (mg/dl) 124.073.1 95.069.0 <0.0001
ApoB (mg/dl) 93.855.8 78.357.7 <0.0001
Data are expressed as mean SD or as number (percentage). At baseline,
TNT patients had been taking atorvastatin 10 mg for 8 weeks.
448 The American Journal of Cardiology (www.ajconline.org)Methods
The main results of the 6 trials included in this analysis
have been published previously and are summarized in
Table 1.8e13 All trials were randomized, double-blinded,
and had placebo or active treatment comparators. Follow-
up was open label, with blinded end point evaluation in
IDEAL and blinded in the other 5 trials. The primary end
points differed among the 6 trials, and for this study, major
CV events were deﬁned as CV death, myocardial infarction,
resuscitated cardiac arrest, and stroke. The analysis plan for
this study was designed prospectively to answer questions
related to gender differences with statins in low-density li-
poprotein (LDL) cholesterol lowering, CV events, and
discontinuation rates due to AEs and creatine kinase (CK)
elevations.
To assess the impact of gender on lipid lowering,
changes from baseline in LDL-C, high-density lipoprotein
(HDL) cholesterol, triglycerides, and non-HDL cholesterol
over time by treatment were analyzed. Within each gender,
treatment comparisons were performed using an analysis-of-
covariance model containing baseline and treatment.
Treatment-by-gender interactions were computed to assess
consistency of treatment effect by gender. IDEAL and TNT
were pooled and presented by treatment (atorvastatin 80 mg,
simvastatin 20 to 40 mg/atorvastatin 10 mg). SPARCL was
summarized separately, and CARDS, ASCOT, and ASPEN
were pooled (atorvastatin 10 mg vs placebo for all 3 trials).
To assess the association of LDL and HDL cholesterol on
CV events by gender, the 6 studies were pooled. We eval-
uated major CV events, coronary heart disease (CHD) death,
nonfatal myocardial infarction, stroke, and CV mortality.
Analysis was performed by month 3 LDL cholesterol
gender-speciﬁc quintiles for all studies except ASCOT, in
which month 6 LDL cholesterol was used because month 3
lipids were not collected. Subjects with events occurringbefore month 3 LDL cholesterol or month 6 LDL choles-
terol in ASCOT were excluded from the analysis. Cox
proportional-hazards models adjusting for study and treat-
ment were used and hazard ratios (HRs) were computed
comparing each quintile with the lowest LDL cholesterol
quintile. The p value for trend across the 5 quintiles was
computed. The analysis was performed for men and women
separately. To examine the consistency of LDL cholesterol
effect on events by gender, the interaction between gender
and LDL cholesterol quintiles was computed. This analysis
was repeated using month 3 HDL cholesterol quintiles.
The impact of gender on discontinuation rates was
examined separately for each of the 6 studies. A summary of
discontinuation by treatment, reasons for discontinuations,
Figure 1. Changes in LDL cholesterol in men and women are shown for SPARCL study (top), TNT and IDEAL (middle), and ASPEN, CARDS, and ASCOT
(bottom). Overall, the differences in LDL cholesterol lowering between women and men were small and not clinically signiﬁcant.
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was generated. Statistical comparisons were performed for
men and women using logistic regression comparing the
difference in rates between treatments, and the treatment-by-
gender interaction was computed for overall discontinua-
tions due to AEs. Predictors of discontinuation were
assessed for men and women separately.
An analysis to assess the effect of gender on CK eleva-
tions and AEs was performed for the 5 trials for which this
information was available (CK levels were not measured in
ASCOT). CK levels before treatment were categorized, and
shifts in CK elevations were summarized at the maximum
CK level during the study. Rates of discontinuations due toAEs and treatment emergent myalgia were summarized for
the baseline CK subgroups.
Results
Selected features of the 6 trials are listed in Table 1. Of
the 39,173 patients enrolled in the 6 trials, 9,173 (23.4%)
were women. As listed in Table 2, women were older (63.3
vs 61.6 years), were more likely to have hypertension and
diabetes, weighed less, and had higher LDL and HDL
cholesterol levels at baseline. Mean follow-up for 4 of the
trials was 4-5 years but was shorter in CARDS and
ASCOTeLipid Lowering Arm (ASCOT-LLA) because
Table 3
Cardiovascular event rates in women and men according to quintiles of on-treatment LDL and HDL cholesterol levels
Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 P for trend
Women: LDL-C (mg/dl) <65 65-83 84-103 104-128 >128
Women: event rate 132/1727
(7.64%)
120/1702
(7.05%)
147/1685
(8.72%)
136/1694
(8.03%)
177/1715
(10.32%)
0.009
Men: LDL-C (mg/dl) <66 66-81 82-99 100-123 >123
Men: event rate 469/5430
(8.64%)
512/5807
(8.82%)
519/5574
(9.31%)
592/5598
(10.58%)
554/5603
(9.89%)
<0.0001
Women: HDL-C (mg/dl) <43 43-50 51-57 58-65 >65
Women: event rate 186/1792
(10.38%)
162/1613
(10.04%)
137/1809
(7.57%)
128/1658
(7.72%)
108/1760
(6.14%)
<0.0001
Men: HDL-C (mg/dl) <38 38-42 43-47 48-54 >54
Men: event rate 604/5549
(10.88%)
635/5905
(10.75%)
455/5667
(8.03%)
492/5674
(8.67%)
485/5734
(8.46%)
<0.0001
Table 4
On-treatment LDL cholesterol quintiles as predictors of cardiovascular events in women and men
Women Men Gender*trend p-value
HR (Quintile 5 vs 1) Trend p-value HR (Quintile 5 vs 1) Trend p-value
Major cardiovascular event 1.69 (1.25-2.27) <0.001 1.34(1.14,1.57) <0.001 0.920
Non-fatal myocardial infarction 2.14 (1.30-3.52) 0.004 1.43 (1.12-1.83) 0.007 0.864
Coronary heart disease death 1.16 (0.75-1.77) 0.893 1.74 (1.41-2.14) <0.001 0.018*
Cardiovascular death 1.37 (0.80-2.35) 0.416 1.39 (1.05-1.84) 0.009 0.526
Stroke 1.63 (1.06-2.52) 0.022 1.08 (0.83-1.41) 0.533 0.184
Quintiles 5 versus 1 are presented to show the direction of effect; trend p values are shown to assess trend across the quintiles.
* The gender*trend p value of 0.018 changes to 0.56 after adjustment for diabetes, HDL cholesterol levels, hypertension, and smoking.
Table 5
Discontinuation rates due to AEs in women and men
Study Men Women Treatment*gender interaction
Study Drug Comparator
Drug
Study Drug Comparator
Drug
TNT 9.6% 8.3% 13.9% 10.4% 0.620
IDEAL 8.3% 4.1% 15.1% 4.6% 0.010
SPARCL 1.8% 1.4% 3.2% 1.9% 0.396
CARDS 7.3% 7.8% 9.0% 8.8% 0.968
ASPEN 2.8% 3.1% 2.4% 3.0% 0.262
ASCOT 5.6% 5.4% 7.1% 7.7% 0.391
Study drug consisted of atorvastatin 80 mg in TNT, IDEAL, and SPARCL and atorvastatin 10 mg in CARDS, ASPEN, and ASCOT-LLA. Comparator drug
was atorvastatin 10 mg in TNT, simvastatin 20 to 40 mg in IDEAL, and placebo in SPARCL, CARDS, ASPEN, and ASCOT-LLA.
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occurred in 3,083 of 30,000 men (10.3%) and 823 of 9,173
women (9.0%).
Changes in lipids were generally similar in women and in
men, as shown in Figure 1 for LDL cholesterol. High-dose
atorvastatin lowered LDL and non-HDL cholesterol
compared with the moderate dose slightly more in men than
in women in the pooled TNT and IDEAL patients (p ¼
0.003 for treatment-by-gender interaction at 3 months for
LDL cholesterol), but the absolute difference was small. No
gender difference was seen with atorvastatin 80 mg in
SPARCL. In contrast, atorvastatin 10 mg lowered LDL and
non-HDL cholesterol compared with placebo slightly more
in women than in men in the pooled CARDS, ASPEN, andASCOT-LLA patients (p ¼ 0.02 for treatment-by-gender
interaction at 6 months for LDL cholesterol), but this dif-
ference was also small and did not persist consistently at
subsequent visits.
To consider the impact of discontinuation rates on lipid
changes, the analysis was repeated after excluding all
evaluations that occurred after the last treatment date.
Overall, the decreases in LDL were slightly larger, and for
IDEAL and TNT, the treatment-by-gender interactions from
months 3 to 24 were no longer signiﬁcant (data not shown).
In SPARCL, atorvastatin 80 mg slightly but signiﬁcantly
increased HDL cholesterol in men, but in women, the in-
crease was smaller and not statistically signiﬁcant, while no
consistent gender differences in HDL cholesterol were seen
Table 6
Treatment-emergent myalgia rates by baseline CK level in women and men
CK (mg/dl) Atorvastatin Number Atorvastatin Myalgia Placebo Number Placebo Myalgia Simvastatin Number Simvastatin Myalgia
Women: total 4,481 505 (11.3%) 1,768 120 (6.8%) 841 91 (10.8%)
<ULN 4,226 479 (11.3%) 1,667 113 (6.8%) 765 83 (10.9%)
ULN-3xULN 233 24 (10.3%) 96 7 (7.3%) 74 8 (10.8%)
>3-<5xULN 8 2 (25%) 5 0 1 0
>5xULN 4 0 0 0 1 0
Men: total 14,602 1,373 (9.4%) 3,091 142 (4.6%) 3,556 274 (7.7%)
<ULN 12,563 1,169 (9.3%) 2,536 111 (4.4%) 2,982 231 (7.8%)
ULN-3xULN 1,948 191 (9.8%) 525 31 (5.9%) 553 42 (7.6%)
>3-<5xULN 73 10 (13.7%) 28 0 21 1 (3.7%)
>5xULN 18 3 (16.7%) 2 0 0 0
Atorvastatin 10- and 80-mg doses are combined; simvastatin 20 to 40 mg; ULN ¼ upper limit of normal. Data are from 5 of the 6 trials; CK levels were not
measured in ASCOT.
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No consistent gender differences were seen for the
triglyceride-lowering effect of either dose of atorvastatin.
For major CV events and nonfatal myocardial infarction,
there was a signiﬁcant trend across LDL and HDL choles-
terol quintiles for men and women. The data for major CV
events for LDL and HDL cholesterol quintiles are listed in
Table 3. For HDL cholesterol quintiles, the trend-by-gender
interaction was signiﬁcant (p ¼ 0.0089), indicating that
HDL cholesterol was a stronger predictor of major CV
events in women than in men. For CHD death, CV death,
and all-cause mortality, there was a signiﬁcant trend across
LDL cholesterol quintiles for men but not women; in
contrast, for stroke and non-CV death, we observed the
opposite effect; namely, the observed trend was signiﬁcant
for women (for non-CV death, the trend was in favor of
higher quintiles) and not men.
The unadjusted HRs comparing quintile 5 with quintile 1
in women and men for different end points are listed in
Table 4. Adjusting for diabetes, HDL cholesterol levels,
hypertension and smoking increased the HR for major CV
events for women from 1.69 to 2.10 (95% CI 1.49 to 2.94)
and for men from 1.34 to 1.48 (95% CI 1.22 to 1.79). After
adjustment, the trend-by-gender interaction for CHD death
was no longer statistically signiﬁcant (p ¼ 0.56).
As listed in Table 5, discontinuation rates due to AEs were
slightly higher in women than in men in 4 of the 6 trials;
however, a treatment-by-gender interaction was present only
in IDEAL. The most common AE causing discontinuation in
women was myalgia in IDEAL and ASPEN and elevated
hepatic enzymes in TNTandSPARCL. Increasing age, higher
atorvastatin dose, and number of concomitant medications
were predictive of treatment discontinuation in women and
men (all p values <0.0001) by multivariate analysis. The
presence of diabetes was also predictive in women but not
men (HR 1.33, 95% CI 1.09 to 1.63, p ¼ 0.005, gender-by-
factor interaction p ¼ 0.036).
As listed in Table 6, most subjects did not have signiﬁ-
cant CK elevations and remained in their baseline CK cat-
egories. Rates of myalgia were slightly higher in women
than in men in each of the 3 treatment groups: 11.3% versus
9.4% with atorvastatin, 10.8% versus 7.7% with simva-
statin, and 6.8% versus 4.6% with placebo.Discussion
The results of this study show that the effects of atorvas-
tatin 10 and 80 mg in 6 large randomized trials did not differ
markedly overall in women compared with men. The 10-mg
dose lowered LDL cholesterol levels slightly more in
women than in men, but the 80-mg dose lowered LDL
cholesterol levels slightly more in men. On-treatment LDL,
non-HDL, and HDL cholesterol levels were correlated with
major CV events for women and men, with a marginally
signiﬁcant treatment-by-gender interaction for HDL choles-
terol. Differences were seen for components of the composite
end point, perhaps abetted by the smaller number of women
than men: for CHD death, CV death, and all-cause mortality,
there was a signiﬁcant trend across on-treatment LDL
cholesterol quintiles for men but not for women. For stroke,
the trend across LDL cholesterol quintiles was statistically
signiﬁcant for women but not men. For non-CV deaths, LDL
cholesterol levels were signiﬁcantly correlated in women,
with beneﬁt at higher LDL cholesterol levels.
Differences between women and men in the amount of
LDL cholesterol lowering for the same statin dose have not
been highlighted in previous studies. In a network meta-
analysis of 256,827 patients from 181 trials,14 the in-
vestigators concluded that the proportion of women in a trial
did not inﬂuence the degree of LDL cholesterol lowering
with different statins; however, they did not have access to
patient-level data. The difference in LDL cholesterol
lowering between genders seen in this study is much smaller
than the variation between individuals.
The Cholesterol Treatment Trialists’ Collaboration meta-
analysis of 170,000 patients included 45,495 women.1 Each
1 mmol/L reduction in LDL cholesterol was associated with
a 17% reduction in CV events for women and a 23%
reduction for men (p for heterogeneity ¼ 0.04). This meta-
analysis did not detail other differences between genders,
and meta-analyses that did focus on gender did not have
access to patient level data.4e6 We found no heterogeneity
between genders in the relationship between on-treatment
LDL cholesterol and CV events, but we did for the rela-
tion between on-treatment HDL cholesterol and CV events.
More women than men die from stroke every year, and
fatal plus nonfatal stroke constitutes a higher proportion of
452 The American Journal of Cardiology (www.ajconline.org)CV events in women compared with men.15 In our study,
the association between on-treatment LDL cholesterol and
stroke was stronger in women than men. In patients with
recent stroke or transient ischemic attacks included in
SPARCL, women were older, had higher systolic and lower
diastolic blood pressure, were more likely to have diagnosed
hypertension, and were less likely to smoke cigarettes.16
They also had higher levels of total cholesterol, LDL
cholesterol, HDL cholesterol, and apolipoprotein A1 levels
than men. Despite these differences, a gender-by-treatment
interaction for stroke was not seen, and event reduction
was similar for both genders.
Most studies that evaluated the safety of statins did not
focus speciﬁcally on women17; however, it has been sug-
gested that women may be at a higher risk for statin-induced
myopathy.18 Among the 6 trials included in this report
(Table 5), discontinuation rates due to AEs were higher in
women than men in 4, but a signiﬁcant treatment-by-gender
interaction was present only in IDEAL, the only trial in
which treatment allocation during follow-up was not blin-
ded. In the trials that included atorvastatin 10 mg, myalgia
was the most common reason for drug discontinuation,
while in the atorvastatin 80 mg treatment groups, elevated
hepatic enzymes were the most common cause. The rates of
treatment-related myalgia were slightly higher in women
than in men in the statin and placebo groups. We examined
whether baseline CK elevations could predict on-treatment
myalgia, but CK levels were almost always normal at
baseline, limiting the utility of this approach.
We have not reported gender differences in new-onset
diabetes in these trials, because those data have already
been published. Of the 6 trials, 2 were restricted to subjects
with diabetes at baseline (CARDS and ASPEN). In TNT,
IDEAL, and SPARCL, we have previously reported that the
incidence of new-onset diabetes did not differ between
women and men.19 Gender was also not a factor predictive
of new-onset diabetes in ASCOT.20
The results of this study are relevant to the types of pa-
tients enrolled in the 6 trials. Approximately 40% of the
women across the trials had documented coronary disease
(TNT and IDEAL), about 20% were enrolled for diabetes
(CARDS and ASPEN), 20% for cerebrovascular disease
(SPARCL), and 20% for hypertension and other risk factors
(ASCOT-LLA). Women with hyperlipidemia in the absence
of CV disease, diabetes, or hypertension are not represented,
and the results therefore may not apply to them. Atorvastatin
was used in each trial, and the proﬁle of AEs might be
different with other statins.
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